# v4.23\n\n## Related releases\n\n## Data changes\n

### Gene

```
ADGRG4 Background Updated
ADGRG4 Summary Updated
AFDN Background Updated
AFDN Summary Updated
AGGF1 Background Updated
AGGF1 Summary Updated
MAGI2 Background Updated
MAGI2 Summary Updated
PRKCB Background Updated
PRKCB Summary Updated
ZNF292 Background Updated
ZNF292 Summary Updated
```

### Alteration

```
AFDN Deletion, Mutation Effect, Description Updated
AFDN Deletion, Mutation Effect, Effect Updated
	 New: Likely Loss-of-function
	 Old:
AFDN Deletion, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
AFDN Deletion Added
AFDN Truncating Mutations, Mutation Effect, Description Updated
AFDN Truncating Mutations, Mutation Effect, Effect Updated
	 New: Likely Loss-of-function
	 Old:
AFDN Truncating Mutations, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
AFDN Truncating Mutations Added
AGGF1 Amplification, Mutation Effect, Description Updated
AGGF1 Amplification, Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old:
AGGF1 Amplification, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
AGGF1 Amplification Added
BRCA2 S2835P, Mutation Effect, Description Updated
BRCA2 S2835P, Mutation Effect, Effect Updated
	 New: Inconclusive
	 Old:
BRCA2 S2835P, Mutation Effect, Oncogenic Updated
	 New: Inconclusive
	 Old:
BRCA2 S2835P Added
FLI1 EWSR1-FLI1 Fusion, Mutation Effect, Description Updated
POLE D275V, Mutation Effect, Description Updated
PRKCB Amplification, Mutation Effect, Description Updated
PRKCB Amplification, Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old:
PRKCB Amplification, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
PRKCB Amplification Added
ZNF292 Truncating Mutations, Mutation Effect, Description Updated
ZNF292 Truncating Mutations, Mutation Effect, Effect Updated
	 New: Loss-of-function
	 Old:
ZNF292 Truncating Mutations, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
ZNF292 Truncating Mutations Added
```

### Evidence

```
ABL1 BCR-ABL1 Fusion, Chronic Myelogenous Leukemia, Asciminib, Description Updated
ABL1 BCR-ABL1 Fusion, Chronic Myelogenous Leukemia, Asciminib, Additional Information Updated
AFDN Gene Type, Tumor Suppressor Updated
AGGF1 Gene Type, Oncogene Updated
FLI1 EWSR1-FLI1 Fusion, Ewing Sarcoma, Ewing Sarcoma of Soft Tissue, TK216, Description Updated
KMT2A Fusions, Mixed Phenotype Acute Leukemia with t(v;11q23.3); KMT2A Rearranged, Summary Updated
KMT2A Fusions, Acute Myeloid Leukemia, Summary Updated
KMT2A Fusions, Acute Myeloid Leukemia, Revumenib, Description Updated
KMT2A Fusions, B-Lymphoblastic Leukemia, Lymphoma, Summary Updated
KMT2A Fusions, Other Tumor Types, Summary Updated
KMT2A Fusions, Other Tumor Types Added
KMT2A Fusions, Acute Leukemias of Ambiguous Lineage, Summary Updated
KMT2A Fusions, Acute Leukemias of Ambiguous Lineage, Revumenib, Description Updated
KMT2A Fusions, Acute Leukemias of Ambiguous Lineage, Revumenib, FDA Level Updated
	 New: Fda2
	 Old: no
KMT2A Fusions, Acute Leukemias of Ambiguous Lineage, Revumenib, Level Updated
	 New: 1
	 Old:
KMT2A Fusions, Acute Leukemias of Ambiguous Lineage, Revumenib, Propagation to Other Solid Tumor Types Updated
KMT2A Fusions, Acute Myeloid Leukemia, Revumenib, FDA Level Updated
	 New: Fda2
	 Old: Fda3
KMT2A Fusions, Acute Myeloid Leukemia, Revumenib, Level Updated
	 New: 1
	 Old: 3A
KMT2A Fusions, Acute Myeloid Leukemia, Revumenib, Additional Information Updated
KMT2A Fusions, B-Lymphoblastic Leukemia, Lymphoma, Revumenib, Description Updated
KMT2A Fusions, B-Lymphoblastic Leukemia, Lymphoma, Revumenib, FDA Level Updated
	 New: Fda2
	 Old: Fda3
KMT2A Fusions, B-Lymphoblastic Leukemia, Lymphoma, Revumenib, Level Updated
	 New: 1
	 Old: 3A
KMT2A Fusions, Acute Myeloid Leukemia, Revumenib, Propagation to Other Liquid Tumor Types Updated
KMT2A Fusions, B-Lymphoblastic Leukemia, Lymphoma, Revumenib, Propagation to Other Liquid Tumor Types Updated
KMT2A Fusions, Acute Leukemias of Ambiguous Lineage, Revumenib, Propagation to Other Liquid Tumor Types Updated
KMT2A Fusions, Acute Leukemias of Ambiguous Lineage, Revumenib 1 Added
MAGI2 Gene Type, Tumor Suppressor Updated
MET D1010, 963_1010splice [Exon 14 splice mutations], 963_1010del [Exon 14 in-frame deletions], Exon 14 Deletion, Non-Small Cell Lung Cancer, Capmatinib, Description Updated
MET D1010, 963_1010splice [Exon 14 splice mutations], 963_1010del [Exon 14 in-frame deletions], Exon 14 Deletion, Non-Small Cell Lung Cancer, Capmatinib, Additional Information Updated
NTRK1 G595R, All Solid Tumors, Summary Updated
NTRK1 G595R, All Solid Tumors, Selitrectinib, Description Updated
NTRK1 G595R, All Solid Tumors, Selitrectinib, FDA Level Updated
	 New: Fda3
	 Old: no
NTRK1 G595R, All Solid Tumors, Selitrectinib, Level Updated
	 New: 3A
	 Old:
NTRK1 G595R, All Solid Tumors, Selitrectinib, Propagation to Other Liquid Tumor Types Updated
NTRK1 G595R, All Solid Tumors, Selitrectinib, Propagation to Other Solid Tumor Types Updated
NTRK1 G595R, All Solid Tumors, Selitrectinib 3A Added
NTRK1 G595R, All Solid Tumors, Zurletrectinib, Description Updated
NTRK1 G595R, All Solid Tumors, Zurletrectinib, FDA Level Updated
	 New: Fda3
	 Old: no
NTRK1 G595R, All Solid Tumors, Zurletrectinib, Level Updated
	 New: 4
	 Old:
NTRK1 Fusions, All Solid Tumors, Zurletrectinib, Description Updated
NTRK1 Fusions, All Solid Tumors, Zurletrectinib, FDA Level Updated
	 New: Fda3
	 Old: no
NTRK1 Fusions, All Solid Tumors, Zurletrectinib, Level Updated
	 New: 4
	 Old:
NTRK1 Fusions, All Solid Tumors, Zurletrectinib, Propagation to Other Liquid Tumor Types Updated
NTRK1 Fusions, All Solid Tumors, Zurletrectinib, Propagation to Other Solid Tumor Types Updated
NTRK1 Fusions, All Solid Tumors, Zurletrectinib 4 Added
NTRK1 G595R, All Solid Tumors, Zurletrectinib, Propagation to Other Liquid Tumor Types Updated
NTRK1 G595R, All Solid Tumors, Zurletrectinib, Propagation to Other Solid Tumor Types Updated
NTRK1 G595R, All Solid Tumors, Zurletrectinib 4 Added
NTRK2 Fusions, All Solid Tumors, Zurletrectinib, Description Updated
NTRK2 Fusions, All Solid Tumors, Zurletrectinib, FDA Level Updated
	 New: Fda3
	 Old: no
NTRK2 Fusions, All Solid Tumors, Zurletrectinib, Level Updated
	 New: 4
	 Old:
NTRK2 Fusions, All Solid Tumors, Zurletrectinib, Propagation to Other Liquid Tumor Types Updated
NTRK2 Fusions, All Solid Tumors, Zurletrectinib, Propagation to Other Solid Tumor Types Updated
NTRK2 Fusions, All Solid Tumors, Zurletrectinib 4 Added
NTRK3 G623R, All Solid Tumors, Summary Updated
NTRK3 G623R, All Solid Tumors, Selitrectinib, Description Updated
NTRK3 G623R, All Solid Tumors, Selitrectinib, FDA Level Updated
	 New: Fda3
	 Old: no
NTRK3 G623R, All Solid Tumors, Selitrectinib, Level Updated
	 New: 3A
	 Old:
NTRK3 G623R, All Solid Tumors, Selitrectinib, Propagation to Other Liquid Tumor Types Updated
NTRK3 G623R, All Solid Tumors, Selitrectinib, Propagation to Other Solid Tumor Types Updated
NTRK3 G623R, All Solid Tumors, Selitrectinib 3A Added
NTRK3 G623R, All Solid Tumors, Zurletrectinib, Description Updated
NTRK3 G623R, All Solid Tumors, Zurletrectinib, FDA Level Updated
	 New: Fda3
	 Old: no
NTRK3 G623R, All Solid Tumors, Zurletrectinib, Level Updated
	 New: 4
	 Old:
NTRK3 G623R, All Solid Tumors, Zurletrectinib, Propagation to Other Liquid Tumor Types Updated
NTRK3 G623R, All Solid Tumors, Zurletrectinib, Propagation to Other Solid Tumor Types Updated
NTRK3 G623R, All Solid Tumors, Zurletrectinib 4 Added
NTRK3 Fusions, All Solid Tumors, Zurletrectinib, Description Updated
NTRK3 Fusions, All Solid Tumors, Zurletrectinib, FDA Level Updated
	 New: Fda3
	 Old: no
NTRK3 Fusions, All Solid Tumors, Zurletrectinib, Level Updated
	 New: 4
	 Old:
NTRK3 Fusions, All Solid Tumors, Zurletrectinib, Propagation to Other Solid Tumor Types Updated
NTRK3 Fusions, All Solid Tumors, Zurletrectinib, Propagation to Other Liquid Tumor Types Updated
NTRK3 Fusions, All Solid Tumors, Zurletrectinib 4 Added
PIK3CA Oncogenic Mutations, Breast Cancer, Inavolisib + Palbociclib + Fulvestrant, Description Updated
PIK3CA Oncogenic Mutations, Breast Cancer, RLY-2608 + Fulvestrant, Description Updated
PIK3CA Oncogenic Mutations, All Solid Tumors, RLY-2608, Description Updated
PIK3CA H1047R, All Solid Tumors {excluding Colorectal Cancer}, Summary Updated
PIK3CA H1047R, All Solid Tumors {excluding Colorectal Cancer}, LOXO-783 4 Deleted
PIK3CA H1047R, Breast Cancer, LOXO-783 + Fulvestrant, LOXO-783 + Fulvestrant + Abemaciclib, LOXO-783 + LY3484356, LOXO-783 + LY3484356 + Abemaciclib, LOXO-783 + Aromatase Inhibition Therapy + Abemaciclib, LOXO-783 + Paclitaxel 4 Deleted
PRKCB Gene Type, Oncogene Updated
PRKCB Gene Type, Tumor Suppressor Updated
TP53 Y220C, All Solid Tumors, Rezatapopt, Description Updated
ZNF292 Gene Type, Tumor Suppressor Updated
```
